Drug Profile
Research programme: janus kinase inhibitor - HK inno.N
Alternative Names: JAK inhibitor - HK inno.NLatest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator CJ Cheiljedang Corp.
- Developer HK inno.N
- Class
- Mechanism of Action Janus kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 28 Feb 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea
- 01 Jan 2016 Preclinical trials in Rheumatoid arthritis in South Korea (unspecified route)